Sintilimab Plus Apatinib and SOX as First-line Treatment in Patients With AFP Gastric or Gastroesophageal Junction Adenocarcinoma

NCT06973330 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

AFP Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: SOX regimen combined with Sintilimab and Apatinib

Sponsor

Anhui Provincial Cancer Hospital